About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

GlaxoSmithKline and AstraZeneca Drugs Show Promise In Clinical Trials For Lupus

by Shirley Johanna on November 11, 2015 at 6:53 PM
Font : A-A+

GlaxoSmithKline and AstraZeneca Drugs Show Promise In Clinical Trials For Lupus

Two drugs from GlaxoSmithKline and AstraZeneca have shown promise in systemic lupus erythematosus (SLE), raising the hope of improved treatment for the debilitating disease.

Lupus is an autoimmune disorder that is characterized by joint pain and swelling, rashes on the skin and extreme fatigue. Some patients experience intermittent flare-ups that can lead to severe and even life-threatening symptoms.

Advertisement

GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product that is the first new therapy for the disease in five decades.

In the phase III trial, a 200mg subcutaneous dose of the B-lymphocyte stimulator (BLyS) inhibitor given once a week was found to be more effective in reducing disease activity compared to placebo.
Advertisement

After a year, 61% of the Benlysta group showed reduced disease activity as measured by the SLE Responder Index (SRI) - a standard measure if efficacy - compared to 48% of patients on placebo.

"On the basis of these data, we expect to progress towards global regulatory filings for a belimumab subcutaneous formulation," commented Paul-Peter Tak, head of immuno-inflammation R&D at GSK.

A new phase II trial conducted by AZ on the drug - called anifrolumab (formerly MEDI-546) - is an antibody blocking the type I interferon (IFN) receptor, showed that the drug significantly reduced disease activity and improved symptoms of SLE, including rash and arthritis.

After a year, 51.5% of patients taking a 300mg intravenous dose of anifrolumab once a month achieved an SRI response, compared to 17% of the placebo group.

"The lupus community has been disappointed too often with clinical trial results," commented principal investigator Richard Furie of North Shore-LIJ Health System. "We have been eagerly awaiting clinical data of this magnitude for many years," he added.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Know More About Mitochondria
Top 10 Foods for Decreasing DHT Production and Preventing Hair Fall
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Clinical Trials Clinical Trials - The Past and The Future Clinical Trials - Different Phases of the trial Top Ten Selling Drugs Drugs Banned in India Placebo Effects: Rare Insights Aplastic Anemia 

Most Popular on Medindia

Vent Forte (Theophylline) Hearing Loss Calculator Sanatogen Sinopril (2mg) (Lacidipine) The Essence of Yoga Iron Intake Calculator Color Blindness Calculator Noscaphene (Noscapine) Drug - Food Interactions Calculate Ideal Weight for Infants
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT ONLINE WITH A DOCTOR

×

GlaxoSmithKline and AstraZeneca Drugs Show Promise In Clinical Trials For Lupus Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests